ArticleCancers2021
Interstitial HDR Brachytherapy in the Treatment of Non-Melanocytic Skin Cancers around the Eye.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- The influence of brachytherapy on tooth development: a longitudinal study of pediatric head and neck tumor survivors.BMC oral health · 2026Article
- High-dose-rate brachytherapy for eyelid carcinoma: Implant technique and review.Journal of contemporary brachytherapy · 2025Article
- The irreplaceable art of brachytherapy: A technical note on interstitial high-dose-rate interventional radiotherapy (brachytherapy) in eyelid tumors.Journal of contemporary brachytherapy · 2025Article
- Brachytherapy for eyelid cancers: Re-defining outcomes and esthetics in rare histologies.Journal of contemporary brachytherapy · 2025Article
- Interstitial brachytherapy for periocular nonmelanoma skin cancers: Impact on organ and function preservation.Technical innovations & patient support in radiation oncology · 2024Article
- Surface mold brachytherapy for head and neck non-melanoma skin cancer - local control rates and survival: A retrospective analysis.Journal of contemporary brachytherapy · 2024Article
- Article
- Post-operative interventional radiotherapy (brachytherapy) in advanced ocular surface and eyelid tumors as an alternative to surgical retreatment.European journal of ophthalmology · 2024Article
- Brachytherapy and 3D printing for skin cancer: A review paper.Journal of contemporary brachytherapy · 2024Review
- Treatment of Basal Cell Carcinoma of the Lower Eyelid With High-Dose-Rate Brachytherapy.Cureus · 2024Article
- Dosimetric impact of applying a model-based dose calculation algorithm for skin cancer brachytherapy (interventional radiotherapy).Journal of contemporary brachytherapy · 2023Article
- Article
- ORIFICE (Interventional Radiotherapy for Face Aesthetic Preservation) Study: Results of Interdisciplinary Assessment of Interstitial Interventional Radiotherapy (Brachytherapy) for Periorificial Face Cancer.Journal of personalized medicine · 2022Article
- Innovations in brachytherapy.Taiwan journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundEyelid tumors are rare skin cancers, the most common of which is basal cell carcinoma characterized primarily by local growth. In addition to surgery, radiotherapy is among the basic methods of treatment. External beam radiotherapy is associated with the risk of complications within ocular structures, especially the lens. In the case of interstitial brachytherapy, it is possible to administer a high dose to the clinical target volume (CTV), while reducing it in the most sensitive structures.
methodsThis paper presents the results of an analysis of 28 patients treated with interstitial high dose rate (HDR) brachytherapy for skin cancers of the upper and lower eyelid; medial and lateral canthus; and the cheek, nose and temples with the infiltration of ocular structures. The patients were treated according to two irradiation schedules: 49 Gy in 14 fractions of 3.5 Gy twice a day for 7 days of treatment, and 45 Gy in 5 Gy fractions twice a day for 5 days. The mean follow-up was 22 months (3-49 months).
resultstwo patients (6%) had a relapse: a local recurrence within the irradiated area in one of them, and metastases to lymph nodes in the other. The most common early complication was conjunctivitis (74%), and the most common late complication was dry eye syndrome (59%).
conclusionsInterstitial HDR brachytherapy for skin cancers of the upper and lower eyelid; medial and lateral cants; and the cheek, nose and temples with infiltration of ocular structures is a highly effective, short and relatively low burden type of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.